X

Trial Profile

(MRC Working party on Leukaemia in Adults) Chronic Lymphocytic Leukaemia trial 4: A Randomised Comparison of Chlorambucil, Fludarabine and Fludarabine plus Cyclophosphamide

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fludarabine (Primary) ; Fludarabine (Primary) ; Chlorambucil; Cyclophosphamide; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use

Most Recent Events

01 Sep 2021 Results assessing gene mutations which were speciically associated with death caused by infection published in the Leukemia
08 Dec 2015 Accrual to date is 106%, according to United Kingdom Clinical Research Network record.
01 Jul 2012 Results published in Leukemia and Lymphoma.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com